The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InActivist short-seller Morpheus Research has released a scathing report targeting MakeMyTrip (MMYT), alleging persistent anti-competitive behavior. The report claims the company continues to enforce price parity agreements despite a 2022 ruling and penalty from the Competition Commission of India (CCI). Furthermore, Morpheus Research accuses MakeMyTrip of accounting irregularities and the use of misleading financial metrics to mask its true performance. The short-seller also pointed to an undisclosed CCI investigation that is reportedly expected to conclude in early 2026. These allegations raise significant concerns regarding regulatory compliance and the integrity of the company's financial reporting. Such reports typically trigger downward pressure on stock prices as investors weigh the risks of further regulatory scrutiny and potential legal repercussions.